Evidence map›Paper›PMID 39080589›Full record

ArticleBMC neurology2024

Response to letter to the editor regarding "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries".

Angelo Antonini, K Ray Chaudhuri, Josefa Domingos, Joohi Jimenez-Shahed, Jack Wright, Connie H Yan, Ali Alobaidi, Lars Bergmann, Koray Onuk, Linda Harmer and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy.
K Ray ChaudhuriParkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, UK.
Josefa DomingosEuropean Parkinson's Disease Association (EPDA), Sevenoaks, UK.
Joohi Jimenez-ShahedDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jack WrightAdelphi Real World, Bollington, UK.
Connie H YanAbbVie Inc, North Chicago, IL, USA.
Ali AlobaidiAbbVie Inc, North Chicago, IL, USA.
Lars BergmannAbbVie Inc, North Chicago, IL, USA.
Koray OnukAbbVie Inc, North Chicago, IL, USA.
Linda HarmerAbbVie Inc, North Chicago, IL, USA.
Irene A MalatyFixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, USA. Irene.malaty@neurology.ufl.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.

Indexed as

Parkinson DiseaseAntiparkinson AgentsHumansAntiparkinson Agents5-2-1 criteriaAdvanced Parkinson’s diseaseDevice-aided therapiesPatient identificationScreening performance

Identifiers

PMID39080589
PMCPMC11290257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.